Stockscreener 앱 받기
1.24
0.80%
-0.01
시장 영업 전:
1.25
0.01
+0.81%
Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스
Galectin Therapeutics (NASDAQ: GALT) Updates Corporate Presentation and Discloses Forward-Looking StatementsGalectin Therapeutics Inc. (the “Company”) updated its corporate presentation on January 13, 2025, which will be utilized in interactions such - Defense World
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Wealth Enhancement Advisory Services LLC - Defense World
Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT) - MarketBeat
Comparing Galectin Therapeutics (NASDAQ:GALT) and Avenue Therapeutics (NASDAQ:ATXI) - Defense World
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - The Manila Times
Galectin Therapeutics to Present Breakthrough NAVIGATE Trial Results at MASH-TAG 2025 Conference - StockTitan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Acquires 20,817 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by State Street Corp - Defense World
Galectin Therapeutics director Harold Shlevin purchases $7,539 in common stock - Investing.com Nigeria
Galectin Therapeutics Director Increases Stake Amid Strong Momentum, Despite Trial Setbacks - HPBL
Galectin Therapeutics (NASDAQ:GALT) Lowered to “Sell” Rating by StockNews.com - Defense World
Galectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to "Sell" - MarketBeat
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 41.1% in December - MarketBeat
North American Morning Briefing : Boeing Stock -2- - Marketscreener.com
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Sanctuary Advisors LLC - Defense World
H.C. Wainwright cuts Galectin stock rating to Neutral By Investing.com - Investing.com Canada
Galectin Therapeutics (NASDAQ:GALT) Given “Neutral” Rating at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Galectin Therapeutics (GALT) - MSN
HC Wainwright Reiterates Neutral Rating for Galectin Therapeutics (NASDAQ:GALT) - MarketBeat
Eldred Kary buys $11,044 in Galectin Therapeutics shares By Investing.com - Investing.com Australia
Joel Lewis Sells 56,000 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) Stock - MarketBeat
Insider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Insider Sells 13,654 Shares of Stock - MarketBeat
Galectin Therapeutics Inc. (NASDAQ:GALT) CFO Sells $35,600.00 in Stock - MarketBeat
Eldred Kary buys $11,044 in Galectin Therapeutics shares - Investing.com India
Galectin Therapeutics director Kevin Freeman acquires $8,134 in stock By Investing.com - Investing.com Australia
Galectin Therapeutics director Kevin Freeman acquires $8,134 in stock - Investing.com India
Galectin Therapeutics CEO Lewis Joel sells $49,610 in stock By Investing.com - Investing.com Canada
Galectin Therapeutics director Richard Zordani buys $8,164 in stock By Investing.com - Investing.com Nigeria
Galectin Therapeutics’ chief medical officer sells $12,044 in shares By Investing.com - Investing.com Nigeria
Galectin Therapeutics director Richard Zordani buys $8,164 in stock - Investing.com India
Galectin therapeutics CFO Jack Callicutt sells $35,492 in stock By Investing.com - Investing.com Canada
Galectin Therapeutics CEO Lewis Joel sells $49,610 in stock - Investing.com
Galectin Therapeutics' chief medical officer sells $12,044 in shares - Investing.com
Liver Cirrhosis Therapeutics Market Size in the 7MM was ~USD 3,100 Million in 2023, is further anticipated to increase with a siginificant CAGR by 2034 and estimated DelveInsight - Barchart
Liver Cirrhosis Therapeutics Market Size in the 7MM was ~USD - openPR
Galectin Therapeutics Announces Positive Results from NAVIGATE Clinical Trial - Defense World
Galectin drops as trial for lead asset fails in MASH - MSN
Belapectin shows promise in liver disease trial - Investing.com India
Dow Surges Over 600 Points, Gold Jumps 1.5% - Benzinga
Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint - MarketWatch
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher - Benzinga
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Galectin Therapeutics stock hits 52-week low at $1.23 - Investing.com
Phase III MASH Miss Sends Galectin Stock Tumbling - BioSpace
Dow Surges 100 Points, Carnival Earnings Top Views - Benzinga
Galectin Therapeutics stock hits 52-week low at $1.23 By Investing.com - Investing.com Nigeria
Belapectin shows promise in liver disease trial By Investing.com - Investing.com South Africa
Galectin stock drops after MASH trial data (GALT:NASDAQ) - Seeking Alpha
0.65%
4.62%
자본화:
|
볼륨(24시간):